SCHEMBL403522

SCHEMBL403522

Cc1nnn(C(CCCN)c2ccc(Cl)cc2Cl)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A4 P31645 1/20 0.45
SLC6A3 Q01959 1/20 0.45
HTT P42858 2/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
DPP4 P27487 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
HSD11B1 P28845 1/20 0.32
CNR1 P21554 2/20 0.31
CCR4 P51679 2/20 0.31
LTA4H P09960 1/20 0.31
CYP2C9 P11712 1/20 0.31
PSEN1 P49768 1/20 0.31
PSEN2 P49810 1/20 0.31
APH1B Q8WW43 1/20 0.31
NCSTN Q92542 1/20 0.31
APH1A Q96BI3 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL400931 0.83 SLC6A2 (0.65) CYP2D6SLC6A2SLC6A4SLC6A3HTT
SCHEMBL407330 0.68 SLC6A4 (0.65) CYP2D6SLC6A2SLC6A4SLC6A3DPP4
SCHEMBL405273 0.63 SLC6A2 (0.50) CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL407261 0.63 SLC6A2 (0.37) CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL401681 0.62 SLC6A4 (1.00) CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL406535 0.62 SLC6A2 (0.65) CYP2D6SLC6A2SLC6A4SLC6A3HTT
SCHEMBL407729 0.62 SLC6A2 (0.65) CYP2D6SLC6A2SLC6A4SLC6A3HTT
SCHEMBL406668 0.61 SLC6A2 (0.37) CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL20640452 0.61 ADRA2C (0.52) CYP2D6SLC6A2SLC6A4SLC6A3LMNA
SCHEMBL28926872 0.59 TP53 (0.62) HTTLMNATP53MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101642-B2 3-substituted propanamine compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2012-01-24 US disclosed
US-20100311789-A1 3-Substituted Propanamine Compounds SK BIOPHARMACEUTICALS CO., LTD. (KR) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311789-A1 3-Substituted Propanamine Compounds ADRB3, PNMT, OPRK1 CYP2D6 422/4885SLC6A2 31/4885SLC6A4 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.